Back to Archived Journals » Clinical Oncology in Adolescents and Young Adults » Volume 1

Editorial

Authors Kieran M

Published 29 April 2011 Volume 2011:1 Pages 9—10

DOI https://doi.org/10.2147/COAYA.S20417



Mark Kieran
Dana-Farber Cancer Institute, Boston, MA, USA

Rapid advances in the molecular characterization of cancer have resulted in new approaches to treatment. For greatest impact, targeted agents, in combination with traditional therapies, will need to be tested in each age group and for each disease. Adolescents and young adults are being recognized as a distinct group of patients that unfortunately are under-represented in formal clinical trials and new treatment assessments. The reason for this are multiple and include the lack of insurance coverage for many as they transition to independence from their parents, the sense of invincibility that many young adults feel, the types of tumors observed in these patients, and the lack of coordinated clinical trial consortiums for this age group.

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.